Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Soleno Therapeutics (SLNO) Divestments (2016 - 2017)

Soleno Therapeutics (SLNO) has disclosed Divestments for 2 consecutive years, with $717000.0 as the latest value for Q3 2017.

For Q3 2017, Divestments rose 35750.0% year-over-year to $717000.0; the TTM value through Dec 2017 reached $716000.0, changed N/A, while the annual FY2018 figure was -$172000.0, 124.02% down from the prior year.
Divestments hit $717000.0 in Q3 2017 for Soleno Therapeutics, up from $3000.0 in the prior quarter.
Across five years, Divestments topped out at $717000.0 in Q3 2017 and bottomed at -$6885.0 in Q4 2016.